Pharma BD Deal Intelligence
Merck & Co., Inc. / IOmet Pharma Ltd.
2016 · Acquisition/Merger · $400M · Complete
Announcement Sentiment
67
Positive
Merck acquired UK-based IOmet Pharma, gaining preclinical pipeline of IDO, TDO, and dual IDO/TDO inhibitors to bolster immuno-oncology development program. Financial terms undisclosed; press reports estimate ~$400M total deal value. Strategic combination potential with Keytruda.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Pipeline outcome
Assets Terminated
Assessment window: 10yr post-close.
Key facts
- Announced Jan 11, 2016
- Closed Jan 11, 2016
- Deal value $400M
- Deal type Acquisition/Merger
- Therapeutic area Solid tumors (immuno-oncology)
- Indications Solid tumors (immuno-oncology)
- Key assets IDO/TDO/dual IDO-TDO inhibitor portfolio
- Mechanism Indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO) inhibitors
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals